Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M.

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...

A recommended 150 minutes per week at moderate intensity can help reduce liver inflammation and rid the organ of fat.

Dr. Kellmeyer has contributed to the submission of multiple successful New Drug Appications to the FDA and Marketing Authorization Applications to the European Medicines Agency, among them OLPRUVA® ...

This deal positions GSK to compete with Conshohocken-based Madrigal Pharmaceuticals, whose FDA-approved MASH drug, Rezdiffra, earned $180.1 million last year. GSK’s Chief Scientific Officer Tony Wood ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with liver disease. The company presented positive two-year results from the open ...